Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines

被引：7

作者：

Henson, Brianna ^{[1
]}

Hollingsworth, Hanna ^{[2
]}

Nevois, Erika ^{[3
]}

Herndon, Chris ^{[4
]}

机构：

[1] Wake Forest Baptist Hlth Brenner Childrens Hosp, Winston Salem, NC USA

[2] Parkland Hlth & Hosp Syst, Dallas, TX USA

[3] CVS Pharm, Springfield, IL USA

[4] Southern Illinois Univ Edwardsville, Sch Pharm, 200 Univ Pk Dr, Edwardsville, IL 62026 USA

来源：

JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY | 2020年 / 34卷 / 01期

关键词：

CGRP; migraine; calcitonin gene-related peptide; erenumab; galcanezumab; fremanezumab; DOUBLE-BLIND; EPISODIC MIGRAINE; RECEPTOR ANTAGONISTS; PREVENTIVE TREATMENT; EFFICACY; SAFETY; ANTIBODY; PHASE-2; TRIAL;

D O I：

10.1080/15360288.2019.1690616

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

Migraine is highly prevalent and associated with a large socio-economic burden in the United States. Current preventive medications have variable efficacy and their use is often limited by intolerable side effects. Calcitonin gene-related peptide (CGRP) has been identified as an integral part of migraine pathophysiology. There are currently seven CGRP antagonists under investigation, all of which are undergoing or have completed phase 3 clinical trials. Three of the investigated CGRP antagonists are approved for use within and outside of the United States. The trials have resulted in positive efficacy and safety data. The purpose of this review is to evaluate the seven CGRP antagonists and their future place in therapy.

引用

页码：22 / 31

页数：10

共 19 条

[1]

Allergan PLC, 2018, PR NEWSWIRE

[2]

[Anonymous], ADISINSIGHT DRUGS

[3] Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study [J].

Bigal, Marcelo E. ;

Dodick, David W. ;

Rapoport, Alan M. ;

Silberstein, Stephen D. ;

Ma, Yuju ;

Yang, Ronghua ;

Loupe, Pippa S. ;

Burstein, Rami ;

Newman, Lawrence C. ;

Lipton, Richard B. .

LANCET NEUROLOGY, 2015, 14 (11) :1081-1090

[4] Potential mechanisms of prospective antimigraine drugs: A focus on vascular (side) effects [J].

Chan, Kayi Y. ;

Vermeersch, Steve ;

de Hoon, Jan ;

Villalon, Carlos M. ;

MaassenVanDenBrink, Antoinette .

PHARMACOLOGY & THERAPEUTICS, 2011, 129 (03) :332-351

[5]

D'Amico Domenico, 2008, Neuropsychiatr Dis Treat, V4, P1155

[6] Blocking CGRP in migraine patients - a review of pros and cons [J].

Deen, Marie ;

Correnti, Edvige ;

Kamm, Katharina ;

Kelderman, Tim ;

Papetti, Laura ;

Rubio-Beltran, Eloisa ;

Vigneri, Simone ;

Edvinsson, Lars ;

Brink, Antoinette Maassen Van Den .

JOURNAL OF HEADACHE AND PAIN, 2017, 18

[7] ARISE: A Phase 3 randomized trial of erenumab for episodic migraine [J].

Dodick, David W. ;

Ashina, Messoud ;

Brandes, Jan Lewis ;

Kudrow, David ;

Lanteri-Minet, Michel ;

Osipova, Vera ;

Palmer, Kerry ;

Picard, Hernan ;

Mikol, Daniel D. ;

Lenz, Robert A. .

CEPHALALGIA, 2018, 38 (06) :1026-1037

[8] Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study [J].

Dodick, David W. ;

Goadsby, Peter J. ;

Spierings, Egilius L. H. ;

Scherer, Joel C. ;

Sweeney, Steven P. ;

Grayzel, David S. .

LANCET NEUROLOGY, 2014, 13 (09) :885-892

[9] The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine [J].

Edvinsson, Lars .

HEADACHE, 2017, 57 :47-55

[10] CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment [J].

Edvinsson, Lars .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (02) :193-199

← 1 2 →